Consonance Capital Management’s Corcept Therapeutics CORT Stock Holding History

Consonance Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,882,773	Closed	-$32.1M	–	31
2019 Q2	$32.1M	Sell	2,882,773 -864,680	-23%	-$9.63M	2.27%	17
2019 Q1	$44M	Sell	3,747,453 -2,464,511	-40%	-$30.6M	2.78%	13
2018 Q4	$83M	Buy	6,211,964 +1,173,090	+23%	+$15.5M	6.1%	7
2018 Q3	$70.6M	Buy	5,038,874 +410,457	+9%	+$5.74M	3.8%	15
2018 Q2	$72.8M	Sell	4,628,417 -560,000	-11%	-$9.74M	4.69%	9
2018 Q1	$85.3M	Sell	5,188,417 -591,089	-10%	-$11M	7.8%	3
2017 Q4	$104M	Buy	5,779,506 +1,897,283	+49%	+$34.4M	9.43%	2
2017 Q3	$74.9M	Sell	3,882,223 -1,922,117	-33%	-$28.7M	8.29%	5
2017 Q2	$68.5M	Buy	5,804,340 +634,700	+12%	+$6.9M	8.07%	7
2017 Q1	$56.7M	Buy	+5,169,640	New	+$45.4M	5.94%	8

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Consonance Capital Management's CORT Position: Q3 2019 in Review

Consonance Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 2,882,773 shares — an estimated $32.1M sold.

Consonance Capital Management first reported a position in CORT in Q1 2017 and held it in 10 quarters. The position peaked at $104M in Q4 2017. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

Consonance Capital Management reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
Consonance Capital Management sold 2,882,773 Corcept Therapeutics shares in Q3 2019, an estimated $32.1M.
Consonance Capital Management first reported a position in Corcept Therapeutics in Q1 2017 and held it in 10 quarters.
Consonance Capital Management's Corcept Therapeutics position peaked at $104M in Q4 2017.
193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.